However, it was demonstrated using synthetic triterpenoid RTA 405 that pharmacological activation of Nrf2 may be distinct from genetic activation and does not provide a growth or survival advantage to certain cancer cells, including pancreatic cancer cells. Here, NFE2L2 is linked to cancer.